Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response
- PMID: 16611919
- PMCID: PMC1471997
- DOI: 10.1128/JVI.80.9.4591-4600.2006
Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response
Abstract
Human cytomegalovirus (HCMV) is a ubiquitous human pathogen that infects 40 to 90% of adult human populations. HCMV infections are often asymptomatic in healthy individuals but can cause severe organ and life-threatening disease in immunocompromised patients. The antiviral antibody response to HCMV infection is complex and is known to include virus-neutralizing antibody production against surface glycoproteins encoded by HCMV. We have investigated the human antibody response to a complex of HCMV surface glycoproteins composed of glycoprotein M (gM)/gN, the gene products of the UL100 and UL73 open reading frames. Mouse monoclonal antibodies generated against gM/gN have previously been shown to neutralize HCMV infection of human fibroblasts in vitro. To determine whether human antibodies reactive with the gM/gN complex possess virus-neutralizing properties, we isolated human antibodies reactive with gM/gN from pooled human HCMV hyperimmune globulin by affinity purification using recombinant gM/gN. The affinity-purified human anti-gM/gN antibodies reacted specifically by immunofluorescence with HCMV-infected human fibroblasts and with cells transiently expressing gM/gN, but not with cells transfected with plasmids encoding other immunogenic HCMV proteins. The anti-gM/gN antibodies also reacted specifically only with gM/gN in immunoblot assays using lysates of transfected cells expressing specific HCMV proteins. Last, human anti-gM/gN antibodies efficiently neutralized infectious HCMV in vitro with a capacity comparable to that of human anti-gB antibodies. These data indicated that gM/gN can elicit a virus-neutralizing antibody response in humans infected with HCMV and therefore should be considered a potential candidate for inclusion in prophylactic CMV vaccines.
Figures





Similar articles
-
Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies.PLoS Pathog. 2012;8(10):e1002999. doi: 10.1371/journal.ppat.1002999. Epub 2012 Oct 25. PLoS Pathog. 2012. PMID: 23133379 Free PMC article.
-
Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).J Virol. 2000 Dec;74(24):11881-92. doi: 10.1128/jvi.74.24.11881-11892.2000. J Virol. 2000. PMID: 11090188 Free PMC article.
-
DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.Vaccine. 2007 Apr 30;25(17):3319-27. doi: 10.1016/j.vaccine.2007.01.011. Epub 2007 Jan 16. Vaccine. 2007. PMID: 17287056
-
Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.Clin Investig. 1993 Apr;71(4):270-6. doi: 10.1007/BF00184725. Clin Investig. 1993. PMID: 8386033 Review.
-
Genomic variants among human cytomegalovirus (HCMV) clinical isolates: the glycoprotein n (gN) paradigm.Hum Immunol. 2004 May;65(5):387-94. doi: 10.1016/j.humimm.2004.02.023. Hum Immunol. 2004. PMID: 15172436 Review.
Cited by
-
A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.J Virol. 2016 Aug 12;90(17):7902-19. doi: 10.1128/JVI.00283-16. Print 2016 Sep 1. J Virol. 2016. PMID: 27334585 Free PMC article.
-
Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity.Viruses. 2021 Jun 9;13(6):1106. doi: 10.3390/v13061106. Viruses. 2021. PMID: 34207868 Free PMC article. Review.
-
Human Cytomegalovirus Primary Infection and Reactivation: Insights From Virion-Carried Molecules.Front Microbiol. 2020 Jul 14;11:1511. doi: 10.3389/fmicb.2020.01511. eCollection 2020. Front Microbiol. 2020. PMID: 32765441 Free PMC article. Review.
-
The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Cell Mol Immunol. 2015 Mar;12(2):170-9. doi: 10.1038/cmi.2014.120. Epub 2014 Dec 29. Cell Mol Immunol. 2015. PMID: 25544503 Free PMC article. Review.
-
DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.Hum Vaccin Immunother. 2013 Oct;9(10):2120-32. doi: 10.4161/hv.25750. Epub 2013 Jul 25. Hum Vaccin Immunother. 2013. PMID: 24051429 Free PMC article.
References
-
- Andreoni, M., M. Faircloth, L. Vugler, and W. J. Britt. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23:157-167. - PubMed
-
- Arvin, A. M., P. Fast, M. Myers, S. Plotkin, and R. Rabinovich. 2004. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39:233-239. - PubMed
-
- Britt, W. J. 1984. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135:369-378. - PubMed
-
- Britt, W. J., and D. Auger. 1985. Identification of a 65,000 dalton virion envelope of human cytomegalovirus. Virus Res. 4:31-36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical